Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

Thursday, 16 April 2020

ESMO Colloquium - EGFR TKI: Single agent or in combination?

EGFR-TKI: Single Agent or in Combination Thumb

Room B, Palexpo Geneva, Switzerland, 09:15 – 10:45
View the ESMO Colloquium details

Learning objectives:

  • Learn how to optimise the use of EGFR TKI in EGFR mutant NSCLC 
  • Understand the rationale for possible combination with anti-angiogenics or chemotherapy 
    • Review the level of evidence for such combined uses 
  • Put in perspective the role of immune checkpoint inhibitors in EGFR mutant NSCLC 
    • Address the question of the best sequence or possible upfront combination

This educational activity is provided by ESMO and supported by Lilly

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings